Diabetes Registry Graz for Biomarker Research (GIRO)

M

Medical University of Graz

Status

Enrolling

Conditions

Adiposity
Type 2 Diabetes
Type1diabetes

Treatments

Other: No intervention

Study type

Observational

Funder types

Other

Identifiers

NCT05324488
HS-2015-01

Details and patient eligibility

About

The Diabetes registry for biomarker research Graz is a prospective cohort-study including subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity and dyslipidemia, aiming to collect data, blood and urine samples of all subjects on an annual basis.

Full description

Obesity and diabetes represent probably the most challenging threat to public health in the 21st century. Despite well-controlled established cardiovascular risk factors, the residual risk in subjects with diabetes mellitus is significantly higher than the risk in those without the condition and it is well established that current risk prediction models for cardiovascular disease using established risk factors do not fully explain the future cardiovascular risk. Therefore, biomarker for better risk stratification are needed, in particular in subjects with diabetes mellitus. Prospective cohorts, meticulously clinically phenotyping subjects, regularly following them and collecting biomarker samples is one key approach for finding new biomarker panels, that are predictive of treatment response and future micro- and macrovascular complications. The Diabetes registry for Biomarker Research Graz was initiated in November 2015. Subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity or dyslipidemia are recruited in the outpatient clinic for Diabetes, Lipid and Metabolic Disorders at the University Clinic Graz or in the Rehabilitation Center St. Radegund. As of September 2021, 1250 subjects are recruited. Blood and urine samples samples are collected at baseline and at annual follow up visits as well as data on medical history, diagnoses and medication.

Enrollment

2,000 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 - 99 years
  • Informed consent has to be given in written form
  • At least one of the following diseases:
  • Type 1 diabetes
  • Type 2 diabetes
  • Type 3 diabetes
  • Maturity onset diabetes of young (MODY)
  • Late onset diabetes of the adult (LADA)
  • Adipositas (BMI > 30kg/m2)
  • Lipid metabolism disorder

Exclusion criteria

  • No written informed consent
  • No willingness to participate in this registry

Trial design

2,000 participants in 7 patient groups

Type 1 Diabetes
Description:
Patients with diagnosed type 1 diabetes mellitus
Treatment:
Other: No intervention
Type 2 Diabetes
Description:
Patients with diagnosed type 2 diabetes mellitus
Treatment:
Other: No intervention
Adipositas
Description:
Obese patients with a BMI > 30kg/m2
Treatment:
Other: No intervention
Lipid metabolism disorder
Description:
Patients with disorder of lipid metabolism
Treatment:
Other: No intervention
Type 3 Diabetes Mellitus
Description:
Patients with diagnosed type 3 diabetes mellitus
Treatment:
Other: No intervention
Maturity onset diabetes of the young (MODY)
Description:
Patients with diagnosed MODY
Treatment:
Other: No intervention
Late onset diabetes of the adult (LADA)
Description:
Patients with diagnosed LADA
Treatment:
Other: No intervention

Trial contacts and locations

1

Loading...

Central trial contact

Harald Sourij, MD; Caren Sourij, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems